378,663 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by EVR Research LP

EVR Research LP purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 378,663 shares of the company's stock, valued at approximately $1,761,000. EVR Research LP owned about 0.10% of GoodRx as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GDRX. Raymond James Financial Inc. bought a new stake in GoodRx in the fourth quarter valued at approximately $2,500,000. Russell Investments Group Ltd. bought a new stake in shares of GoodRx in the 4th quarter valued at $314,000. Envestnet Asset Management Inc. acquired a new stake in GoodRx during the 4th quarter worth $84,000. RPO LLC bought a new position in GoodRx during the fourth quarter worth about $52,000. Finally, ExodusPoint Capital Management LP acquired a new position in GoodRx in the fourth quarter valued at about $322,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GDRX. Citigroup lowered their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating for the company in a research report on Friday, January 10th. Truist Financial cut their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. KeyCorp lowered their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Morgan Stanley decreased their target price on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating on the stock in a report on Tuesday, December 17th. Finally, Wells Fargo & Company reduced their price target on GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, GoodRx currently has an average rating of "Moderate Buy" and an average target price of $7.93.

Remove Ads

GoodRx Stock Performance

Shares of GDRX stock remained flat at $4.49 during trading on Tuesday. The stock had a trading volume of 747,078 shares, compared to its average volume of 1,379,576. The business's 50 day moving average is $4.65 and its two-hundred day moving average is $5.04. The company has a market cap of $1.72 billion, a P/E ratio of -149.67, a PEG ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a 52 week low of $3.82 and a 52 week high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.